Hiyashree Sharmah
Hiyashree Sharmah has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Lokman Ali Ahmed
NEF College of Pharmacy, Guwahati, Kamrup, India
5 shared publications - Pooja Patowary
NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions
3 shared publications - Babita Deka
NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions
2 shared publications - Bhargab Jyoti Sahariah
NETES Institute of Pharmaceutical Science
2 shared publications - Abu Saif Mustaque
Department of Pharmacology, NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions,Guwahati, Assam, 781125, India
1 shared publication - Apurba Talukdar
NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions
1 shared publication
Latest Publications
- 4 March 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5053-5066
Current advances in 7-hydroxycoumarin derivatives as potential therapeutic agents for Alzheimer’s disease
Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder, remains a major cause of cognitive decline in the aging population. Current pharmacological interventions provide only symptomatic relief, highlighting the urgent need for novel therapeutic strategies capable of modifying disease progression. Coumarins, particularly 7-hydroxycoumarin and its synthetic derivatives, have attracted considerable interest due to their broad pharmacological potential, including cholinesterase inhibition, monoamine oxidase (MAO) inhibition, antioxidant, anti-amyloidogenic and metal-chelating activities. This review presents a comprehensive analysis of synthetic 7-hydroxycoumarin derivatives reported over the past 15 years as potential anti-Alzheimer agents, classifying them according to their actions on key pathological hallmarks of AD, such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), MAO-B, β-amyloid (Aβ) aggregation, oxidative stress and neuroinflammation. Structure–activity relationship (SAR) analysis reveals that substitutions at the 7-, 3- and 4-positions of the coumarin scaffold critically influence pharmacological potency and selectivity, with aromatic and alkyl amine substitutions generally enhancing enzyme inhibition and neuroprotective effects. Several derivatives exhibited sub-micromolar to nanomolar inhibitory activity against AChE and MAO-B, along with antioxidant and anti-Aβ aggregation properties, supporting their multifunctional behaviour. Overall, this review highlights the therapeutic promise of 7-hydroxycoumarin derivatives as multitarget-directed ligands (MTDLs) and provides valuable insights for the rational design of new lead compounds for Alzheimer’s disease. Graphical abstract
- 4 March 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5053-5066
Current advances in 7-hydroxycoumarin derivatives as potential therapeutic agents for Alzheimer’s disease
Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder, remains a major cause of cognitive decline in the aging population. Current pharmacological interventions provide only symptomatic relief, highlighting the urgent need for novel therapeutic strategies capable of modifying disease progression. Coumarins, particularly 7-hydroxycoumarin and its synthetic derivatives, have attracted considerable interest due to their broad pharmacological potential, including cholinesterase inhibition, monoamine oxidase (MAO) inhibition, antioxidant, anti-amyloidogenic and metal-chelating activities. This review presents a comprehensive analysis of synthetic 7-hydroxycoumarin derivatives reported over the past 15 years as potential anti-Alzheimer agents, classifying them according to their actions on key pathological hallmarks of AD, such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), MAO-B, β-amyloid (Aβ) aggregation, oxidative stress and neuroinflammation. Structure–activity relationship (SAR) analysis reveals that substitutions at the 7-, 3- and 4-positions of the coumarin scaffold critically influence pharmacological potency and selectivity, with aromatic and alkyl amine substitutions generally enhancing enzyme inhibition and neuroprotective effects. Several derivatives exhibited sub-micromolar to nanomolar inhibitory activity against AChE and MAO-B, along with antioxidant and anti-Aβ aggregation properties, supporting their multifunctional behaviour. Overall, this review highlights the therapeutic promise of 7-hydroxycoumarin derivatives as multitarget-directed ligands (MTDLs) and provides valuable insights for the rational design of new lead compounds for Alzheimer’s disease. Graphical abstract
- Open Access
- 13 December 2025
- Published by Springer Nature in Discover Chemistry
- Vol. 2 (1) , 320
Exploring the potential of coumarin-indole hybrid scaffold as promising pharmacological agents: a review
- 13 December 2025
- Published by Springer Nature in Discover Chemistry
- Vol. 2 (1) , 320
Open AccessExploring the potential of coumarin-indole hybrid scaffold as promising pharmacological agents: a review
- 14 August 2025
- Published by Elsevier in Journal of the Indian Chemical Society
- Vol. 102 (10)
Coumarin-indole hybrids: synthesis, characterization & anti-inflammatory evaluation
- 14 August 2025
- Published by Elsevier in Journal of the Indian Chemical Society
- Vol. 102 (10)
Coumarin-indole hybrids: synthesis, characterization & anti-inflammatory evaluation
- Open Access
- 2 July 2025
- Published by Elsevier in Brain Disorders
- Vol. 19
A concise review of synthetic xanthone derivatives for Alzheimer's disease
- 2 July 2025
- Published by Elsevier in Brain Disorders
- Vol. 19
Open AccessA concise review of synthetic xanthone derivatives for Alzheimer's disease
- 28 May 2025
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 119, 108523
Design and synthesis of novel xanthone-thiazole hybrid derivatives as potent anti-inflammatory agent
- 28 May 2025
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 119, 108523
Design and synthesis of novel xanthone-thiazole hybrid derivatives as potent anti-inflammatory agent